Deep Breath Intelligence, the expert in Molecular Breath Analysis, announces collaboration with Löwenstein Medical
Rotkreuz, Switzerland, Sept 24, 2021
DBI, the expert in Molecular Breath Analysis applying artificial intelligence (AI) for state-of-the-art data interpretation announced the collaboration with Löwenstein Medical, Löwenstein Medical leader in sleep and respiratory medicine, based in Germany.
“We are excited to announce the collaboration with Löwenstein Medical, one of the leading companies in sleep and respiratory medicine” announced Prof. Malcolm Kohler, Co-Founder and Delegate of the Board of DBI. “Together with Löwenstein Medical we initiated a study on OSAS (Obstructive Sleep Apnoea Syndrome) using participants’ breath samples to apply DBI’s patterned analytical algorithms to provide results with high accuracy and resolution.”
Mr. Benjamin Löwenstein, Managing Director of Löwenstein Medical stated: “For us as a family-owned company it is utmost important to partner with innovative companies and start-ups as DBI and invest into research and development. We are convinced that we will gain further insights by this important study for our future portfolio, which will result in important insights for of our future patient treatment”.